Endo International | ENDP - Des Atouts



Des Atouts Changement Date
AbbVie USD 133.96B 62M 2025-12
Amarin USD 670.78M 10.96M 2025-12
ANI Pharmaceuticals USD 1.44B 32.22M 2025-12
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Coherus Biosciences USD 258.34M 258.18M 2025-12
Eli Lilly USD 112.48B 2.46B 2025-12
Heron Therapeutics USD 255.88M 6.93M 2025-12
Hikma Pharmaceutical USD 5.67B 117M 2025-12
Ligand Pharmaceuticals USD 1.56B 83.86M 2025-12
Merck USD 129.55B 12.02B 2025-09
Novartis USD 110.95B 3.66B 2025-12
Pacira USD 1.26B 32.66M 2025-12
Perrigo USD 8.54B 1.55B 2025-12
Pfizer USD 208.73B 2.64B 2025-09
Phibro Animal Health USD 1.41B 20.03M 2025-12
Supernus Pharmaceuticals USD 1.45B 32.89M 2025-12
Takeda JPY 15.41T 938.47B 2025-12
Teva Pharmaceutical Industries USD 40.75B 892M 2025-12
Xeris Pharmaceuticals USD 383.53M 13.34M 2025-12
Zoetis USD 15.47B 308M 2025-12